Wave Health Rated a Leading ePRO Platform for Oncology in 2022 Systematic Review
In 2020, a systematic review out of Cedars Sinai evaluated 41 patient-reported outcome (PRO) apps for cancer and rated Wave Health App the highest overall. More recently, researchers at the University of Manchester and the Christie NHS Foundation Trust performed a similar systematic review in which Wave Health’s technology was once again validated as a leading ePRO platform for oncology. Learn more about the 2022 findings in this post.
The University of Manchester and the Christie NHS Foundation Trust are two major entities in cancer care, research, and education in the UK. The systematic review — published in the International Journal of Medical Informatics in November of 2022 — focused on patient-facing cancer mobile apps that enable the collection of PRO (patient-reported outcomes) data. Specifically, it examined several pillars of these apps: functionality, quality, and ability to integrate with electronic health records.
Out of 405 apps available for iOS and Android users, 12 met the eligibility criteria to be evaluated. Functionality and quality were assessed using two validated scales: The IMS Institute for Healthcare Informatics functionality score and the Mobile App Rating Scale (MARS).
chemoWave, the first iteration of Wave Health App created primarily for cancer patients, was ranked in the top two apps included in the review in terms of functionality and quality — with scores well above average in both validated scales.
The review also called out chemoWave as the first app of its kind to conduct consumer-level integration of wearable data, capturing the benefit of increased accuracy compared to self-reported data alone. This model has since been adapted by many others in the industry.
chemoWave has since expanded into a more robust ePRO platform, currently known as Wave Health, serving patients going through treatment for cancer and other chronic illnesses. With increased user engagement, more intuitive UI, added languages — and various other enhancements — this positive assessment of the technology that is at the core of Wave Health is nothing short of promising as we continue to improve the platform.
Coupled with the 2020 Cedars Sinai results, the findings of this systematic review provide Wave Health with multi-market validation as a top ePRO solution in oncology — in both the U.S. and the UK.
More and more, experts are recognizing the power of enabling cancer patients to self-manage symptoms through mobile applications and become empowered partners in their care. chemoWave and Wave Health have consistently been named leaders in this space.
